Spero's news cycle is a catalyst parade—GSK's NDA resubmission, Phase 3 promise, and institutional buying. The stock's chilling at a neutral RSI (49.8), but WMAs are converging bullishly. Volume spiked on the May 14 breakout, confirming real interest, not noise. The chart shows a rounded bottom forming. Big Call: BUY. The technicals are warming up to the fundamental story. 🚀 #AntibioticEdge

Alright, listen up. The big story here is GSK resubmitting that NDA for tebipenem. That's the FDA catalyst this stock lives and dies for. 🧪 Technically? The vibe is cautiously bullish. The 9-period EMA just crossed *above* the 21-period, and the RSI is climbing out of neutral territory into strength. Volume's decent, and the price action is holding above recent lows, trying to build a base. The chart's coiling up, waiting for the FDA news. It's a high-risk, high-reward speculative play. If you believe in the FDA green light, this is a speculative BUY. Just know you're betting on a binary event. #CatalystPlay

GSK's NDA resubmission for their oral antibiotic is the real rocket fuel here. 🚀 The stock just blasted through its 9-day WMA with conviction, and the RSI at 70 says the market's buying the hype. Volume confirms it's not a fluke. This looks like a speculative BUY on the FDA catalyst, but watch for a pullback if the RSI gets too greedy. #BiotechBets

GSK just resubmitted their NDA for that oral antibiotic—huge deal. 📜 The stock’s been consolidating after that monster run-up, and the RSI is cooling off right around 50, which is healthy. Volume’s steady, not panicky. Feels like it’s coiling before the next FDA catalyst. This is a BUY on the dip for the pending news play. #AntibioticArb 💊

GSK just resubmitted their NDA for that oral antibiotic—huge step toward FDA approval! 🎯 The stock's waking up: RSI is climbing out of the "meh" zone into healthy momentum, and it's pushing above both key moving averages. Volume is perking up on the up days. This looks like the market is starting to price in real potential. BUY the rumor before the approval news. #AntibioticArb

The news is pure fire with that GSK-partnered antibiotic win! 🔥 But the stock's digesting those massive gains. RSI is neutral, volume's cooling, and it's stuck between key moving averages. Classic "buy the rumor, sell the news" vibe. I'd wait for a fresh catalyst. HOLD for now. #PauseBeforeThePounce

"Boom! SPRO just got the golden ticket—their Phase 3 trial stopped early for *efficacy*? That’s like a mic drop moment. 🎤📈 The stock exploded (hello, 155M volume!), but RSI is screaming *overbought* at 92—yeah, we’re in meme-stock territory. Short-term? Might pull back to cool off. But long-term? If GSK’s involved, this could be a slow-burn rocket. BUY the dip if you’ve got diamond hands. 💎 #BiotechBets"